Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Poxel SA (POXEL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.67 +0.01    +1.97%
- Closed. Currency in EUR ( Disclaimer )
  • Volume: 495,428
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.66 - 0.73
Type:  Equity
Market:  France
ISIN:  FR0012432516 
Poxel SA 0.67 +0.01 +1.97%

Poxel SA Company Profile

 
Read the Poxel SA company profile to learn more about the business and the management team. View Poxel SA facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

55

Equity Type

ORD

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Contact Information

Address Immeuble Le Sunway 259-261 Avenue Jean JaurEs
Lyon, 69007
France
Phone 33 4 37 37 20 10
Fax 33 4 37 70 88 15

Top Executives

Name Age Since Title
Thomas Kuhn - 2009 Co-Founder, CEO & Director
Harold E. Lebovitz - - Member of Scientific Advisory Board
Mohammed Khoso Baluch - 2012 Independent Chairman of the Board
Kohjiro Ueki - - Member of Scientific Advisory Board
Pascale Boissel 57 2015 Independent Director
Masato Kasuga - 2019 Member of Scientific Advisory Board
Richard N. Kender 67 2015 Independent Director
Kenneth Cusi - 2019 Member of Scientific Advisory Board
Marc Engelen - 2021 Member of Scientific Advisory Board
Stephan Kemp - 2021 Member of Scientific Advisory Board
Keith van Haren - 2021 Member of Scientific Advisory Board
Ralph A. Defronzo - 2019 Member of Scientific Advisory Board
Edouard Guillet - 2022 Observer to the Board of Directors
Philip Newsome - 2021 Member of the Scientific Advisory Board
Hirotaka Watada - - Member of Scientific Advisory Board
Vlad Raziu - 2020 Member of the Scientific Advisory Board
S. Ali Fatemi - 2021 Member of Scientific Advisory Board ?
Stephen A. Harrison - 2019 Member of Scientific Advisory Board
Quentin Anstee - 2020 Member of the Scientific Advisory Board
Arun J. Sanyal - 2020 Member of the Scientific Advisory Board
John F. Amatruda - - Member of Scientific Advisory Board
Wataru Ogawa - - Member of Scientific Advisory Board
Fanny Mochel - 2021 Member of Scientific Advisory Board
Jaspreet Singh - 2021 Member of Scientific Advisory Board
Kohei Kaku - 2019 Member of Scientific Advisory Board
Gregory Steinberg - 2020 Member of Scientific Advisory Board
Florian Eichler - 2021 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

POXEL Price Commentary

Write your thoughts about Poxel SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Patrick Mccrea
Patrick Mccrea Jun 02, 2021 12:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Noone trusts Kuhn - after the lies before Metavant withdrew he lost all credence .
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email